The newest generation of GLP-1 drugs are being hailed by some as “miracle drugs” for the treatment of obesity. But GLP-1s are expensive, insurance coverage is limited, and not everyone with obesity can and or wants to take them. In this episode, which is based on Goldman Sachs Research’s latest Top of Mind report, obesity medicine physician Dr. Fatima Cody Stanford and Jonathan Gruber, professor of economics and chairman of the Economics Department at MIT, discuss how large the addressable market for GLP-1s actually is and the implications for US fiscal health.
If you want more insights from Goldman Sachs, make sure to visit GS.com and sign up for Briefings, a weekly newsletter from Goldman Sachs about trends spanning markets, industries, and the global economy.
Why Technology is Not a Bubble
Hallo Tech: Germany Adapts to the Digital Age
Getting Clarity on Personal Finance's Mobile Shift
Beneath Trade Clouds, China's Transition Opens Opportunities
Why Healthcare is (Finally) Chasing Consumers
What Happened to the American Pension?
At the Movies: Battling Box-Office Blues in an Age of Streaming
Beyond VR and AR: Extended Reality to Transform Our Lives as Consumers
eSports: The New Global Pastime
Oil Investing Enters "The Age of Restraint"
Is Bitcoin a (Bursting) Bubble?
From Mobile Wallets to Blockchain: How Fintech is Growing Up
In Their Own Words: 10,000 Small Businesses on Challenges to Growth
The Rate Stuff: What Markets Are Saying About the Macro Outlook
How Podcasts Are Creating The "Second Golden Age of Audio"
(Un)Steady as She Goes: 2018 Investment Outlook
"Once-in-a-Generation" Energy Shift...Plus Investment Banking Outlook for Latin America
President Trump, Year Two: What's Next on the Agenda?
Closer Than You Think: What the Future Looks Like to Venture Capital
In the Face of Brexit, Business as Usual in Europe... But For How Long?
Create your
podcast in
minutes
It is Free
The emPOWERed Half Hour
TED Radio Hour
FT Alphachat
Freakonomics Radio
Odd Lots
Slate Money